Naproxcinod 750 mg non-inferior to naproxen in the reduction of knee OA symptoms .
Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: A 13-week prospective, randomized, multicenter study
Osteoarthritis Cartilage. 2010 May;18(5):629-39. Epub 2010 Feb 16918 patients (>=40 yr) with osteoarthritis (OA) of the knee and managed with oral NSAIDs or acetaminophen, were randomized to 4 groups of either naproxcinod (750 or 375 mg), naproxen (50 mg) or a placebo. At study conclusion (i.e. 13 weeks), naproxcinod was found to be well-tolerated and did not significantly elevate blood pressure more than naproxen. Naproxcinod's clinical efficacy is statistically superior to placebo for symptom control of knee OA, and the 750 mg dosage was significantly non-inferior to naproxen 500 mg for pain, function and the patient's overall rating of disease status.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
